MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-19-2026
Guardant Health Retained Earnings 2011-2026 | GH
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Guardant Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.99 B | -2.58 B | -2.14 B | -1.66 B | -1.01 B | -607 M | -353 M | -281 M | -196 M | -108 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -108 M | -2.99 B | -1.19 B |
Quarterly Retained Earnings Guardant Health
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.77 B | -2.67 B | -2.58 B | -2.47 B | -2.36 B | -2.26 B | -2.14 B | -1.95 B | -1.87 B | -1.8 B | -1.66 B | -1.52 B | - | -1.13 B | -1.01 B | -917 M | -809 M | -712 M | -607 M | -607 M | -607 M | -607 M | -353 M | -353 M | -353 M | -353 M | -281 M | -281 M | -281 M | -281 M | -196 M | -196 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -196 M | -2.77 B | -1.16 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
-77.3 M | $ 13.71 | -0.22 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
-335 M | $ 8.62 | 0.23 % | $ 574 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 155.46 | 1.83 % | $ 7.71 B | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 25.56 | 0.95 % | $ 710 M | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 17.01 | 3.4 % | $ 906 M | USA |
 |
DexCom
DXCM
|
2.43 B | $ 64.24 | -1.56 % | $ 25.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | $ 103.57 | 0.29 % | $ 19.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
590 M | $ 14.77 | 0.61 % | $ 447 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
-462 M | $ 17.88 | -6.63 % | $ 2.32 B | USA |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 2.83 | -1.05 % | $ 91.8 K | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 98.33 | 0.9 % | $ 8.11 B |  Irlanda |
 |
Danaher Corporation
DHR
|
46.9 B | $ 187.32 | 0.57 % | $ 134 B | USA |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 164.72 | 1.1 % | $ 28.3 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 118.94 | 2.92 % | $ 18.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 199.7 | -0.46 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.45 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
348 M | $ 111.51 | -0.06 % | $ 33.9 B | USA |
 |
BioNano Genomics
BNGO
|
-693 M | $ 1.11 | -0.89 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
-349 M | $ 9.0 | -0.99 % | $ 255 M | Israel |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 173.74 | 0.49 % | $ 24.2 B |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.09 | -2.78 % | $ 1.97 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
4.6 M | - | - | $ 79.8 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 450.41 | 1.48 % | $ 13 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 16.52 | 0.12 % | $ 370 M | USA |
 |
Celcuity
CELC
|
-272 M | $ 114.22 | 3.11 % | $ 4.51 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 7.88 | -1.25 % | $ 1.01 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
OPKO Health
OPK
|
-2.07 B | $ 1.19 | 2.59 % | $ 826 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 187.85 | -1.29 % | $ 18.5 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.66 | -3.92 % | $ 432 M | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.33 | 4.72 % | $ 399 M | USA |